- Home
- KBH vs BBIO Comparison
KBH vs BBIO Comparison
Compare KBH & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBH
- BBIO
- Stock Information
- Founded
- KBH 1957
- BBIO 2015
- Country
- KBH United States
- BBIO United States
- Employees
- KBH N/A
- BBIO N/A
- Industry
- KBH Homebuilding
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KBH Consumer Discretionary
- BBIO Health Care
- Exchange
- KBH Nasdaq
- BBIO Nasdaq
- Market Cap
- KBH 6.1B
- BBIO 5.6B
- IPO Year
- KBH 1987
- BBIO 2019
- Fundamental
- Price
- KBH $66.50
- BBIO $32.98
- Analyst Decision
- KBH Hold
- BBIO Strong Buy
- Analyst Count
- KBH 13
- BBIO 13
- Target Price
- KBH $76.21
- BBIO $48.33
- AVG Volume (30 Days)
- KBH 1.6M
- BBIO 3.1M
- Earning Date
- KBH 01-13-2025
- BBIO 02-20-2025
- Dividend Yield
- KBH 1.50%
- BBIO N/A
- EPS Growth
- KBH 20.24
- BBIO N/A
- EPS
- KBH 8.45
- BBIO N/A
- Revenue
- KBH $6,930,086,000.00
- BBIO $217,765,000.00
- Revenue This Year
- KBH $5.06
- BBIO $2,306.75
- Revenue Next Year
- KBH $0.91
- BBIO N/A
- P/E Ratio
- KBH $7.90
- BBIO N/A
- Revenue Growth
- KBH 8.10
- BBIO 2209.77
- 52 Week Low
- KBH $58.48
- BBIO $21.62
- 52 Week High
- KBH $89.70
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- KBH 45.34
- BBIO 50.78
- Support Level
- KBH $64.77
- BBIO $35.74
- Resistance Level
- KBH $69.64
- BBIO $36.99
- Average True Range (ATR)
- KBH 2.11
- BBIO 1.72
- MACD
- KBH 0.22
- BBIO -0.57
- Stochastic Oscillator
- KBH 25.15
- BBIO 30.85
About KBH KB Home
KB Home is an American construction company that focuses on residential construction in United States. The company builds single-family homes and communities across different geographical segments which include West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.